Breaking News

Goodwin Biotechnology Inks First Commercial Contract

Company will showcase expertise in bringing a product from clinical trials through commercial supply.

Goodwin Biotechnology Inc. (GBI) signed their first master supply agreement for commercializing an antibody. With the development of this new partnership, GBI’s integrated contract development and manufacturing organization (CDMO) biologics services will showcase their expertise in bringing a product from clinical trials through commercial supply while providing manufacturing of both drug substance and drug products. “This is a major milestone in our journey and a validation of...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters